Fintepla FDA Approval History
Last updated by Judith Stewart, BPharm on July 6, 2022.
FDA Approved: Yes (First approved June 25, 2020)
Brand name: Fintepla
Generic name: fenfluramine
Dosage form: Oral Solution
Company: Zogenix, Inc.
Treatment for: Dravet Syndrome, Lennox-Gastaut Syndrome
Fintepla (fenfluramine) is an amphetamine derivative indicated for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome in patients 2 years of age and older.
- Fenfluramine was originally developed as an appetite suppressant and sold under the brand name Pondimin until it was withdrawn from the U.S. market in 1997.
Development timeline for Fintepla
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.